Mouse Anti-ERBB2 Recombinant Antibody (clone SAIC-02A-7) (CAT#: FAMAB-1131CQ)

Figure 1 ELISA data from screening recombinant monoclonal antibodies using recombinant proteins or overexpressed lysates.

ELISA data were reduced using Prism software to calculate the 50% binding point (B50%). The B50% values should not be interpreted as absolute numbers that define mAb performance (i.e., not analogously to affinity constants); instead, the B50% values can be used as relative values to compare the performances of the mAb within this group of mAbs.

Schoenherr, R. M., Saul, R. G., Whiteaker, J. R., Yan, P., Whiteley, G. R., & Paulovich, A. G. (2015). Anti-Peptide Monoclonal Antibodies Generated for Immuno-Multiple Reaction Monitoring-Mass Spectrometry Assays Have a High Probability of Supporting Western blot and ELISA*[S]. Molecular & cellular proteomics, 14(2), 382-398.

Figure 2 Images of Western blots from screening the recombinant and hybridoma monoclonal antibodies (mAbs) using recombinant proteins, overexpressed lysates, and 6 breast cancer NCI60 cell line lysates.

The purified mAbs were run as controls alongside the recombinant proteins or the overexpressed lysate-proteins. Because the mAbs' protein targets (except for TSHB and CGB) were expected to be detected in breast cancer cell lines. For the Western blots using the NCI60 breast cancer cell lines.

Schoenherr, R. M., Saul, R. G., Whiteaker, J. R., Yan, P., Whiteley, G. R., & Paulovich, A. G. (2015). Anti-Peptide Monoclonal Antibodies Generated for Immuno-Multiple Reaction Monitoring-Mass Spectrometry Assays Have a High Probability of Supporting Western blot and ELISA*[S]. Molecular & cellular proteomics, 14(2), 382-398.